Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.50 EUR
−6.79 M EUR
9.18 M EUR
1.68 M
About MARINOMED BIOTECH AG
Sector
CEO
Andreas Grassauer
Headquarters
Korneuburg
Website
Founded
2006
ISIN
ATMARINOMED6
FIGI
BBG00MKMQ109
Marinomed Biotech AG is a biopharmaceutical company, which engages in the development of therapies based on patent protected technology platforms. It operates through the following segments: Immunology, Virology, and Other. The company was founded by Andreas Grassauer and Eva Prieschl-Grassauer in 2006 and is headquartered in Korneuburg, Austria.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of MARI is 15.75 EUR — it has increased by 0.96% in the past 24 hours. Watch MARINOMED BIOTECH AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange MARINOMED BIOTECH AG stocks are traded under the ticker MARI.
MARI stock has risen by 4.65% compared to the previous week, the month change is a 75.00% rise, over the last year MARINOMED BIOTECH AG has showed a −49.19% decrease.
MARI reached its all-time high on Feb 19, 2021 with the price of 147.00 EUR, and its all-time low was 2.00 EUR and was reached on Aug 15, 2024. View more price dynamics on MARI chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MARI stock is 12.50% volatile and has beta coefficient of 0.32. Track MARINOMED BIOTECH AG stock price on the chart and check out the list of the most volatile stocks — is MARINOMED BIOTECH AG there?
Today MARINOMED BIOTECH AG has the market capitalization of 26.69 M, it has decreased by −1.89% over the last week.
Yes, you can track MARINOMED BIOTECH AG financials in yearly and quarterly reports right on TradingView.
MARINOMED BIOTECH AG is going to release the next earnings report on Apr 16, 2025. Keep track of upcoming events with our Earnings Calendar.
MARI net income for the last quarter is −2.13 M EUR, while the quarter before that showed −1.19 M EUR of net income which accounts for −78.84% change. Track more MARINOMED BIOTECH AG financial stats to get the full picture.
No, MARI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 52.00 employees. See our rating of the largest employees — is MARINOMED BIOTECH AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MARINOMED BIOTECH AG EBITDA is −4.94 M EUR, and current EBITDA margin is −63.40%. See more stats in MARINOMED BIOTECH AG financial statements.
Like other stocks, MARI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MARINOMED BIOTECH AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MARINOMED BIOTECH AG technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MARINOMED BIOTECH AG stock shows the neutral signal. See more of MARINOMED BIOTECH AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.